3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
39
Neoplasms
16
Neoplasm Metastasis
8
Colorectal Neoplasms
5
Thyroid Neoplasms
3
Skin Neoplasms
2
Recurrence
2
Leukemia, Hairy Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Histiocytosis, Langerhans-Cell
1
Heterotaxy Syndrome
1
Hepatoblastoma
1
Glioma
1
Interventions
atezolizumab
1
alectinib
1
Vemurafenib
1
Fruit
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Genomic Instability
×
Vemurafenib
×
Clear all
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled